Takeda Pharmaceutical Company Limited logo
Takeda Pharmaceutical Company Limited TAK
$ 18.11 -1.76%

Quarterly report 2022-Q1
added 06-29-2022

report update icon

Takeda Pharmaceutical Company Limited Market Cap 2011-2026 | TAK

As of March 04, 2026 Takeda Pharmaceutical Company Limited has a market cap of $ 28.3 B


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Takeda Pharmaceutical Company Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
20.3 B 56.2 B 35.2 B 33.1 B 38.8 B 37.6 B 40.4 B 35.3 B 43 B 34.3 B 38.3 B

All numbers in JPY currency

Indicator range from annual reports

Maximum Minimum Average
56.2 B 20.3 B 37.5 B

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
4.09 M $ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
598 M $ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
1.97 M - -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
2.77 B $ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
962 M $ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
364 M - 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
98 M - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
8.67 B $ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
13.1 B $ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
6.33 M - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
308 M - -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 8.52 -2.46 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
423 M - - $ 789 M usaUSA
Certara Certara
CERT
1.08 B $ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
160 M - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
3.58 M - -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
231 M - -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
52.7 M - - $ 231 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
155 M $ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
3.04 B $ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
291 M $ 0.99 -3.28 % $ 72.7 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
94.1 M $ 17.75 -0.79 % $ 852 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
551 M - - $ 1.2 B usaUSA
CohBar CohBar
CWBR
5.31 M - -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
5.58 M - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
109 M - -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
1.2 B - - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
3.04 B $ 20.02 -4.67 % $ 3.29 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
114 M $ 17.54 -3.36 % $ 450 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
73.7 M - - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
3.86 M - 7.55 % $ 38.1 M usaUSA